Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

Bousquet OBSanticoagulant, prophylactic doseanticoagulant, curative doseCOVID 19 hospitalizedNA
-/- inconclusive
    Bousquet OBSanticoagulant, prophylactic dosecontrolCOVID 19 hospitalizedNA
    -/- suggested
    • suggested 57 % decrease in deaths

    COVID-19 severe or critically meta-analysis

    Tang OBSanticoagulant, prophylactic dosecontrolCOVID-19 severe or criticallyserious
    99/350 inconclusive

      PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
      Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).